AbbVie targets $24B in 2025 sales from Skyrizi and Rinvoq, outlines robust mid-single-digit growth

Earnings Call Insights: AbbVie Inc. (NYSE:ABBV) Q4 2024

Management View

• CEO Rob Michael highlighted AbbVie’s strong Q4 2024 performance, which exceeded initial guidance with $56.3 billion in total net revenues for the year, up 4.6% operationally, despite $5 billion in U.S. Humira erosion. He emphasized the consistent outperformance